MigVax’s corona

subunit vaccine

MigVax's Vaccine
  • The MigVax vaccine is based on a vaccine developed for Infectious Bronchitis Virus which is a coronavirus that infects chickens. The vaccine was developed over the past 4 years in an attempt to immunize chickens and prevent the jump to humans (bird flu). The vaccine was successfully tested in chickens and not only was able to demonstrate neutralizing antibodies and cell-mediated immunity but more importantly, the vaccine prevented infection in immunized chickens from IBV challenge. To the best of our knowledge, this is the first vaccine to demonstrate prevention of challenge in an in-vivo setting.

  • Based on comparison of the IBV and COVID-19 it was seen that the basis of the chicken vaccine could provide a significant basis for the generation of a human vaccine

​​Advantages of MigVax’s

COVID-19 Subunit vaccine

  • Platform technology

  • Ease of switching

  • Oral administration

  • Triple-arm immunity

  • Safety

  • Efficient and cost-effective large-scale manufacturing

  • The MigVax approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This approach (again based on the IBV vaccine) generates three kinds of immunological response: 1. mucosal immunity- IgA 2. Blood-based immunity-IgG 3. Cell mediated immunity.

  • Mucosal immunity can prevent infection via the oropharynx. This is significant because it has the chance to prevent a detrimental immune response that may result with only IgG based immunity. Cell mediated immunity, may help clear viral infected cells.

  • On the manufacturing side, the vaccine is made using bacterial fermentation, thus the ability to manufacture millions of doses quickly is easily attainable.

  • Based on actual in vivo efficacy in preventing infection, oral based vaccine and three pronged immunity gives the MigVax approach a unique standing among the other approaches. In addition to significant advantages in manufacturing and cost.

  • A proof-of-concept was achieved using an Avian coronavirus sequence for vaccination of chickens against the Avian Infectious Bronchitis (IBV) virus.

  • Definition of specific structural motifs of the corona S and N proteins, sufficient for induction of effective immune response.

  • Development of three chimeric proteins for carrying three distinct structural domains, with enhanced mucosal activity for mucosal vaccination.

  • Development of an E. coli-based protein expression system that produces and secretes the chimeric proteins to the growth media.

  • Proof-of-concept for safety, specific antibody induction, activation of the cellular immune response, and protection against the challenge, was performed in two medium-scale animal studies, in chicken models and Avian corona H120 IBV.

  • Development of fermentation media and process for protein production, following pharma regulations and GMP standards.    

  • Platform technology: MigVax claims its human vaccine development, based on the development of the avian corona virus IBV vaccine, is a generic system for developing subunit corona virus vaccines. The system includes 3 protein elements (one S and two Ns) fused with an adjuvant carrier protein.

  • Ease of switching: The basis of the current MigVax vaccine is built upon the ability to take avian corona virus proteins and convert them to human corona proteins, making it a viable platform for vaccine development with the ability to adapt against the high rate of COVID-19 virus mutation.[1] This rapid switch to newer mutated proteins is an important advantage compared to other technologies.

  • Oral administration: This has a 2-fold effect. Firstly, the ease of administration, especially essential in mass vaccination; and secondly, the mucosal immunity at the site of administration and site of natural virus port of entry – oral mucosa, tonsils, adenoids.

  • Triple-arm immunity: As mentioned above, the MigVax approach is believed to have three kinds of immunal response: mucosal, through site of administration; humoral, through neutralizing antibodies to S protein; and cellular, induced by N proteins component of the vaccine (mucosal IgA, IgG and T-cell response).

  • Safety: no live viral particles; triple-arm immunity may defend from antibody-dependent enhancement

  • Efficient and cost-effective large-scale manufacturing: This is critical in the case of mass vaccination and may be the limiting factor for other technologies; traditional and confirmed technologies, no risk involved (as opposed to newer technologies).​

The Main Achievements of the Program
Advantages of the MigVax Vaccine
MIGAL grants its SPV MigVax exclusive worldwide license to use its vaccine technology
  • LinkedIn
  • Facebook
  • RSS

© 2020 by MigVax Ltd. All rights reserved.